Suresh Bugide
Overview
Explore the profile of Suresh Bugide including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bugide S, Reddy D, Malvi P, Gupta R, Wajapeyee N
iScience
. 2024 May;
27(5):109800.
PMID: 38741708
Hepatocellular carcinoma (HCC) currently lacks effective therapies, leaving a critical need for new treatment options. A previous study identified the anaplastic lymphoma kinase (ALK) amplification in HCC patients, raising the...
2.
Khumukcham S, Penugurti V, Bugide S, Dwivedi A, Kumari A, Kesavan P, et al.
J Biol Chem
. 2023 Oct;
299(11):105311.
PMID: 37797694
While the role of endocytosis in focal adhesion turnover-coupled cell migration has been established in addition to its conventional role in cellular functions, the molecular regulators and precise molecular mechanisms...
3.
Bugide S, Edwards Y, Gupta R, Green M, Wajapeyee N
Proc Natl Acad Sci U S A
. 2023 Jan;
120(4):e2218118120.
PMID: 36652476
Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFRi) are approved for treating EGFR-mutant lung adenocarcinoma (LUAD), emergence of acquired resistance limits their clinical benefits. Several mechanisms for acquired...
4.
Dutta R, Guruvaiah P, Reddi K, Bugide S, Bandi D, Edwards Y, et al.
NAR Cancer
. 2022 Nov;
4(4):zcac035.
PMID: 36338541
Breast cancer is a leading cause of cancer-related deaths among women, and current therapies benefit only a subset of these patients. Here, we show that ubiquitin-conjugating enzyme E2T (UBE2T) is...
5.
Chava S, Bugide S, Malvi P, Gupta R
iScience
. 2022 Aug;
25(8):104752.
PMID: 35942091
Melanoma is a highly aggressive skin cancer that frequently metastasizes, but current therapies only benefit some patients. Here, we demonstrate that the serine/threonine kinase cell division cycle 7 (CDC7) is...
6.
Chava S, Bugide S, Zhang X, Gupta R, Wajapeyee N
iScience
. 2022 May;
25(5):104211.
PMID: 35494243
Oncogenic mutations in the gene account for 15-20% of lung adenocarcinoma (LUAD) cases. However, the mechanism for EGFR driven tumor development and growth is not fully understood. Here, using an...
7.
Bugide S, Gupta R, Green M, Wajapeyee N
Proc Natl Acad Sci U S A
. 2021 Jul;
118(30).
PMID: 34301901
Enhancer of zeste homolog 2 (EZH2) is a histone H3 lysine 27 methyltransferase that has been shown to function as an oncogene in some cancers. Previous reports have largely focused...
8.
Chava S, Bugide S, Edwards Y, Gupta R
Oncogenesis
. 2021 Jul;
10(7):48.
PMID: 34253709
Ovarian cancer is the leading cause of gynecological malignancy-related deaths. Current therapies for ovarian cancer do not provide meaningful and sustainable clinical benefits, highlighting the need for new therapies. We...
9.
Rawat V, Malvi P, Della Manna D, Yang E, Bugide S, Zhang X, et al.
Oncogene
. 2021 Mar;
40(13):2448-2462.
PMID: 33674745
Metabolic deregulation, a hallmark of cancer, fuels cancer cell growth and metastasis. Here, we show that phosphoserine phosphatase (PSPH), an enzyme of the serine metabolism pathway, is upregulated in patient-derived...
10.
Gupta R, Malvi P, Parajuli K, Janostiak R, Bugide S, Cai G, et al.
Proc Natl Acad Sci U S A
. 2020 May;
117(22):12341-12351.
PMID: 32430335
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Currently, there is no effective therapy for PDAC, and a detailed molecular and functional evaluation of PDACs is...